来自官方财务报表的收入、利润与现金流历史。
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $831M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M | $50M | $27M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| 毛利 | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | $49M | $26M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| 毛利率% | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% | 97.3% | 96.7% | 98.6% | 97.2% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| 营业利润（EBIT） | $6M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M | ($3M) | ($28M) | ($41M) | ($36M) | ($32M) | ($27M) | ($20M) | ($20M) | ($12M) | ($26M) |
| 营业利润率% | 0.8% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% | -6.9% | -104.0% | -400.7% | -1096.8% | — | — | -69827.6% | -9420.6% | -2540.5% | -8701.4% |
| 净利 | $55M | $100M | $140M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M | ($6M) | ($31M) | ($46M) | ($38M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($25M) |
| 净利润率 % | 6.6% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% | -12.7% | -118.2% | -444.2% | -1150.5% | — | — | -69537.9% | -9598.6% | -2401.0% | -8460.2% |
| EBITDA | $23M | $68M | $163M | $126M | $116M | $128M | $130M | $114M | $90M | $53M | $10M | ($3M) | ($27M) | ($41M) | ($36M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($26M) |
| 每股收益（EPS） | $0.42 | $0.83 | $1.23 | $0.95 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.39 | $-0.38 | $-0.38 | $-0.43 | $-0.34 | $-1.09 |
| 已发行股数 (M) | 118M | 120M | 113M | 112M | 116M | 126M | 124M | 123M | 127M | 125M | 116M | 107M | 101M | 100M | 93M | 83M | 68M | 52M | 47M | 34M | 23M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 CORT 交互式查看器。 /companies/us/CORT
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms